small molecule

UPTRAVI

SELEXIPAG

Loss of exclusivityJune 2037latest FDA-listed patent expiry

CompanyACTELION PHARMACEUTICALS US INC

Drug detail

Brand name	UPTRAVI
Active ingredient	SELEXIPAG
Strength	0.15MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	May 2026
Marketing status	RX

Listed patents

Patent	Expires	Type
10821108*PED	June 2037	—
10828298*PED	June 2037	—
10828298	December 2036	product
10821108	December 2036	product
8791122*PED	February 2031	—
9284280*PED	December 2030	—
8791122	August 2030	substance, product
9284280	June 2030	use U-1831
9173881*PED	February 2030	—
9173881	August 2029	use U-1798
7205302*PED	April 2027	—
7205302	October 2026	substance, product

Regulatory exclusivity

Code	Expires
PED	November 2029
NS	May 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from ACTELION PHARMACEUTICALS US INC